Venlafaxine : A New Dimension for the Treatment of Major Depression. Satellite Symposium. Copenhagen (DNK), 1994/09/21.
When selecting an antidepressant, a number of factors must be considered.
These considerations are summarized under the mnemonic STEPS :
Payment (eg, cost-effectiveness), and Simplicity of use.
Venlafaxine is the first of a new class of antidepressants that selectively blocks the serotonin and noradrenaline uptake pumps without blocking muscarinic, histaminergic and adrenergic receptors or inhibiting sodium fast channels.
Because venlafaxine avoids these mechanisms of action, it has a wide therapeutic index, an improved tolerability profile and a reduced risk of causing pharmacodynamically mediated drug-drug interactions when compared to tricyclic antidepressants (TCAs).
In contrast to some other new antidepressants, venlafaxine also avoids effects on cytochrome P450 which are likely to cause clinically meaningful, pharmacokinetically mediated drug-drug interactions.
The effects on the uptake pumps of both serotonin and noradrenaline appear to be responsible for some of venlafaxine's unique features in terms of antidepressant efficacy, including its ascending antidepressant dose-response curve and its apparent rapid onset of antidepressant action at the upper end of its clinically relevant dosing range. (...)
Mots-clés Pascal : Venlafaxine, Etat dépressif, Trouble humeur, Toxicité, Efficacité traitement, Coût, Economie santé, Article synthèse, Homme, Antidépresseur, Psychotrope, Chimiothérapie, Inhibiteur recapture, Sérotonine, Noradrénaline
Mots-clés Pascal anglais : Venlafaxine, Depression, Mood disorder, Toxicity, Treatment efficiency, Costs, Health economy, Review, Human, Antidepressant agent, Psychotropic, Chemotherapy, Reuptake inhibitor, Serotonin, Norepinephrine
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0426618
Code Inist : 002B02B02. Création : 19/12/1997.